Literature DB >> 12445193

Inhibition of IgE production by the imidazoquinoline resiquimod in nonallergic and allergic donors.

Birgit Frotscher1, Katrin Anton, Margitta Worm.   

Abstract

The aim of this study was to examine whether the immune modulator resiquimod, which belongs like imiquimod to the imidazoquinolines, is capable of influencing IgE synthesis. Peripheral blood mono-nuclear cells from normal donors and patients with atopic dermatitis and with seasonal allergic rhinitis were analyzed in the presence of resiquimod, anti-CD40+interleukin-4 stimulation for induction of IgE, and anti-CD40+interleukin-4 in the presence of resiquimod, respectively. Our data show that spontaneous IgE production was inhibited in the presence of resiquimod, which was strongest at 10 ng per ml in both groups of allergic patients. Inhibition of IgE production after anti-CD40+interleukin-4 stimulation in the presence of resiquimod (10 ng per ml) was comparable between all the groups. In normal donors median inhibition of IgE synthesis was 93%, in seasonal allergic rhinitis patients 77%, and in patients with atopic dermatitis 72%. In order to rule out antiproliferative effects of resiquimod, which might influence IgE production, we also studied proliferation of peripheral blood mononuclear cells from normal donors, which remained unchanged in the presence of resiquimod at 0.1-10 ng per ml but was inhibited at 100 or 1000 ng per ml. In search of possible mechanisms responsible for the observed inhibition of IgE production, we analyzed the expression and production of molecules that are known to modulate IgE production, namely CD23 and interferon-gamma. CD23 expression on B cells was lower in the presence of resiquimod (10 ng per ml) in anti-CD40+interleukin-4 stimulated cells, whereas interferon-gamma was strongly induced (4-6-fold) by resiquimod (10 ng per ml). Furthermore, by using neutralizing interferon-gamma monoclonal antibodies, we show that inhibition of IgE production occurred in an interferon-gamma-dependent manner. Taken together our results show that resiquimod is a potent modulator of IgE production in vitro in normal but also in allergic donors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12445193     DOI: 10.1046/j.1523-1747.2002.19531.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  11 in total

Review 1.  Translational mini-review series on Toll-like receptors: Toll-like receptor ligands as novel pharmaceuticals for allergic disorders.

Authors:  M Goldman
Journal:  Clin Exp Immunol       Date:  2007-02       Impact factor: 4.330

2.  The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept).

Authors:  Valentina Taverniti; Simone Guglielmetti
Journal:  Genes Nutr       Date:  2011-04-16       Impact factor: 5.523

Review 3.  Recent advances in treatment strategies for atopic dermatitis.

Authors:  Thomas Christian Roos; Stefan Geuer; Sabine Roos; Harald Brost
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 4.  The therapeutic potential of Toll-like receptor 7 stimulation in asthma.

Authors:  Matthew G Drake; Elad H Kaufman; Allison D Fryer; David B Jacoby
Journal:  Inflamm Allergy Drug Targets       Date:  2012-12

5.  Isolation and phenotypic characterization of mucosal nasal lymphocytes by direct ex vivo analysis.

Authors:  Christin Wolfram; Claudia Rasche; Heike Audring; Michael Wahls; Margitta Worm
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-09-03       Impact factor: 2.503

6.  Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4+ T cells from a Th2 to a Th1 response.

Authors:  Tae S Kim; Bok Y Kang; Daeho Cho; Seung H Kim
Journal:  Immunology       Date:  2003-07       Impact factor: 7.397

7.  TLR3 and TLR7 modulate IgE production in antigen induced pulmonary inflammation via influencing IL-4 expression in immune organs.

Authors:  Liesu Meng; Xiaojing He; Wenhua Zhu; Xudong Yang; Congshan Jiang; Qingzhu Sun; Simeng Zhang; Qian Xue; Xinfang Xie; Shemin Lu
Journal:  PLoS One       Date:  2011-02-25       Impact factor: 3.240

Review 8.  Holding the Inflammatory System in Check: TLRs and Their Targeted Therapy in Asthma.

Authors:  Zhiyong Dong; Lingxin Xiong; Weijie Zhang; Peter G Gibson; Ting Wang; Yanjiao Lu; Guoqiang Wang; Hui Li; Fang Wang
Journal:  Mediators Inflamm       Date:  2016-05-04       Impact factor: 4.711

Review 9.  The Interplay between Host Immunity and Respiratory Viral Infection in Asthma Exacerbation.

Authors:  Ferdaus Mohd Altaf Hossain; Jin Young Choi; Erdenebileg Uyangaa; Seong Ok Park; Seong Kug Eo
Journal:  Immune Netw       Date:  2019-09-09       Impact factor: 6.303

10.  Targeting of Immune Cells by Dual TLR2/7 Ligands Suppresses Features of Allergic Th2 Immune Responses in Mice.

Authors:  Jonathan Laiño; Andrea Wangorsch; Frank Blanco; Sonja Wolfheimer; Maren Krause; Adam Flaczyk; Tobias-Maximilian Möller; Mindy Tsai; Stephen Galli; Stefan Vieths; Masako Toda; Stephan Scheurer; Stefan Schülke
Journal:  J Immunol Res       Date:  2017-10-24       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.